Plain-English translation of NCT07040228 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a combination of three medications—regorafenib, toripalimab, and albumin-bound paclitaxel—together to treat advanced pancreatic cancer in people who have already tried two other standard treatments. The study has two phases: first, researchers will find the right dose of regorafenib that patients can safely tolerate; then, they will test whether this medication combination actually helps shrink tumors and extend survival.
Pancreatic cancer is very difficult to treat, and people whose cancer continues to grow after two rounds of standard therapy have very few good options left. This trial exists to see whether combining these three medications—which work in different ways—might offer a new hope for patients in this difficult situation.
You likely qualify if…
You likely don't qualify if…
You will receive the three medications through intravenous infusions (IV) and take one medication by mouth in repeating cycles, with treatment visits happening every 3 weeks. You will continue this treatment until your cancer stops responding, side effects become too severe, or your doctor recommends stopping. The trial includes regular blood tests, scans to measure your tumor, and checkups to monitor how you're tolerating the medications.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
China